Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473794 · ClinicalTrials.gov registry record
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
A clinical trial of Pancreas Cancer and Pancreatic Neoplasms, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT04473794: Recruiting study of Pancreas Cancer and Pancreatic Neoplasms, sponsored by Johns Hopkins University.
NCT04473794 is a study of Pancreas Cancer and Pancreatic Neoplasms that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 5,000 participants, above the 815-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (513% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04473794, a study of Pancreas Cancer and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study are to determine the natural history of pancreatic cysts and to propose and prospectively validate a diagnostic approach and model for prediction of mucinous versus non-mucinous, and malignant versus non-malignant, pancreatic cysts using a combination of clinical, radiologic, and biomarker characteristics.
Primary Outcome
Compcyst is part of the new standard of care diagnosis of precancerous and benign cystic lesions. Patient charts will be reviewed for clinical, radiological, surgical and pathologic information (all combined into a composite) that will be used to determine if Compcyst as part of the new standard of care is better than the diagnostic measure in the old standard of care in detecting precancerous and benign cystic lesions. Patient records over a 15-year period will be reviewed.
Conditions Studied
Study Locations (1)
Maryland
- The Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2036-08-01 |
What NCT04473794 shows while recruiting
NCT04473794 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 815-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (513% higher).
The record links to 2 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04473794 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04473794 about?
NCT04473794 is a clinical study titled "Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts". The aims of this study are to determine the natural history of pancreatic cysts and to propose and prospectively validate a diagnostic approach and model for prediction of mucinous versus non-mucinous, and malignant versus non-malignant, pancreatic cysts using a combination of clinical, radiologic, ...
What is the current status of trial NCT04473794?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2022-07-20. Estimated completion is 2036-08-01.
What conditions does trial NCT04473794 study?
This clinical trial studies the following conditions: Pancreas Cancer, Pancreatic Neoplasms.
Who is sponsoring clinical trial NCT04473794?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04473794 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04473794's enrollment target sits among peer trials
5,000 3rd of 54 higher than 51 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI